Baidu Health and GSK Announce Strategic Collaboration to Advance Disease Prevention Initiatives

On July 29, Baidu Health entered into a strategic partnership with GlaxoSmithKline (GSK), a global leader in biopharmaceuticals. The two parties will deeply integrate their respective strengths, leveraging GSK’s medical and scientific expertise and Baidu Health’s technological advantages to launch multiple disease education initiatives, starting with herpes zoster prevention as a pilot program. They will also gradually explore deeper collaboration in the prevention of other diseases, thereby improving public access to high-quality health resources. Meanwhile, the two sides will continue to cooperate on projects in various fields, including digital innovation, based on cutting-edge technologies such as artificial intelligence.

 GSK China Signs Agreement with Baidu Health

Relevant data indicate that China is currently in a stage of rapid population aging. As of 2022, the number of people aged 60 and above in China reached 280 million, accounting for 19.9% of the total population, making it the country with the largest elderly population in the world. Alongside China’s aging process, there are approximately 1.56 million new cases of herpes zoster among individuals aged 50 and above each year, leading to an increasingly severe disease burden. The treatment and prevention of herpes zoster have become urgent challenges to address. To this end, both parties have designated herpes zoster prevention as a pilot disease area of focus in their strategic cooperation.

Baidu Health is a health management platform independently incubated and developed by Baidu. It serves over 100 million users in the medical and healthcare sector on a daily basis, fulfilling more than 200 million precise medical and healthcare-related searches per day. Its business operations span five major scenarios: health science popularization services, online consultation services, health e-commerce services, internet hospital services, and digital specialized disease alliances.

As a global leading vaccine enterprise with a century-long legacy, GSK is committed to providing more than 20 innovative vaccine products across multiple disease areas, delivering lifelong health protection solutions for countless families. In 2022, its R&D investment exceeded USD 6.6 billion, ranking among the top pharmaceutical companies worldwide.

Mao Ji, General Manager of Pharmaceutical Marketing at Baidu Health, stated that Baidu will continue to leverage digital innovation to collaborate with partners in breaking down medical information barriers for middle-aged and elderly users, promoting proactive health management among this demographic, and facilitating the maturation of China’s senior health market.